I admire him and anyone in the fight, but I go on FOX and all interviews and interview 8 times a day and wrote and publish, with McCullough et al. seems the attention got to his head, calm down Alex

Berenson should calm down, show respect, and step back, he is now questioning ivermectin? He is questioning us? We who have been at the forefront day 1, we who have written the book on early treatment?

He is late to the table yet wants to school us? When the damage is locked in? He is the authority, on what? In his mind. He should go read what I and others have been writing for 2 years and what we have been saying…

Come on Alex, relax yourself.

Who the hell does he think he is and he goes on FOX, does not get challenged…gets soft balls and he talks wonky stuff too, some very questionable like ‘long COVID is not real’…

Look I don't like when people insult each other this way and use their 15 minutes to do it…when often they cant stand in the shoes of whom they attack…

Maybe he seeks attention? Maybe this is to sell books?

Maybe he should go on with me and we be asked some real tough questions…maybe…

This is Malone’s initial reply to the attack by Berenson…

Bushwhacked by Alex Berenson on Fox News

Professional jealousy is an ugly thing

Robert W Malone MD, MS

Jan 15

Alex Bereonson goes on Fox News and directly calls me a liar to my face and says I didn’t invent RNA vaccines.

Unprofessional, rude and an asshole to boot.

But beyond that, I think we can all assume CONTROLLED OPPOSITION.

So, for Alex, who evidently doesn’t know how to do an internet search, find a patent and read it - I will make it easy for him.

First - couple of proff of concept experiments conducted in 1988 -from the patents issued in 1989.

Early Patents priority dates from 1989

The first patents:

• Lipid-mediated polynucleotide administration to deliver a biologically active peptide and to induce a cellular immune response (includes mRNA). P Felgner, JA Wolff, GH Rhodes, R Malone, D Carson. Assigned to Vical, Inc and licensed to Merck. No. 7,250,404, date of issue: 7/31/07 Cited in 105 articles. Priority Date: 3/21/1989.

• Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected (includes mRNA). P Felgner, JA Wolff, GH Rhodes, Robert W Malone, D Carson. Assigned to Vical, Inc and licensed to Merck. US Pat. Ser. No. 6,867,195 B1. Date of issue: 3/15/05. Priority Date: 3/21/1989.

• Generation of an immune response to a pathogen (includes mRNA). P Felgner, JA Wolff, GH Rhodes, Robert W Malone, D Carson. Assigned to Vical, Inc and licensed to Merck. US Pat. Ser. No. 6,710,035. Date of issue: 3/23/04. Citations: 39 articles. Priority Date: 3/21/1989.

• Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human (includes mRNA). P Felgner, JA Wolff, GH Rhodes, Robert W Malone, D Carson. Assigned to Vical, Inc, licensed to Merck. US Pat. Ser. No. 6,673,776. Date of issue: 1/6/04. Priority Date: 3/21/1989.

• Methods of delivering a physiologically active polypeptide to a mammal (includes mRNA). P Felgner, JA Wolff, GH Rhodes, Robert W Malone, D Carson. Assigned to Vical, Inc, licensed to Merck. US Pat. Ser. No. 6,413,942. Date of issue: 7/2/02. (cited in 150 articles). Priority Date: 3/21/1989.

• Induction of a protective immune response in a mammal by injecting a DNA sequence (includes mRNA). P Felgner, JA Wolff, GH Rhodes, Robert W Malone, D Carson. Assigned to Vical, licensed to Merck. US Pat. Ser. No. 6,214,804, date of issue: 4/10/01. Cited in 360 articles. Priority Date: 3/21/1989.

• Induction of a protective immune response in a mammal by injecting a DNA sequence (includes mRNA). P Felgner, JA Wolff, GH Rhodes, Robert W Malone, D Carson. Assigned to Vical, Inc, licensed to Merck. US Pat. Ser. No. 5,589,466. Date of issue: 12/31/96. Cited in 899 articles. Priority Date: 3/21/1989.

• Delivery of exogenous DNA sequences in a mammal (includes mRNA). Assigned to Vical, Inc, licensed to Merck. P Felgner, JA Wolff, GH Rhodes, Robert W Malone, D Carson. US Pat. Ser. No. 5,580,859. Date of issue: 12/3/96. Cited in 1244 articles. Priority Date: 3/21/1989.

• Generation of antibodies through lipid mediated DNA delivery (includes mRNA). P Felgner, JA Wolff, GH Rhodes, Robert W Malone, D Carson. Assigned to Vical, Inc, licensed to Merck. US Pat. Ser. No. 5,703,055. Date of issue: 12/30/97. Cited in 419 articles. Priority Date: 3/21/1989.

  Below are some of the descriptions of the invention taken from the above patents - priority date 1989.

One of my papers and other patents on this subject area (1988-2000)

• A novel approach to study packaging of retroviral RNA by RNA transfection (Abstract). RW Malone, P. Felgner, I. Verma. RNA Tumor Viruses, May 17-18, 1988. Cold Spring Harbor (the first in a series of papers/abstracts on RNA transfection).

• mRNA Transfection of cultured eukaryotic cells and embryos using cationic liposomes. Malone RW. Focus. 1989; 11:61-8

• The SALK patent that was filed with the USPTO on 3/21/1989. Note that the cover letter hides this - and says it was filed on 3/29/89 - the sane date as all the VICAL patents, showing that there was collusion. WRITTEN BT ME IN 1988.

• THE VERY FIRST mRNA VACCINE EXPERIMENTAL DATA 1990 (from Vical to patent office)

• Cationic liposome-mediated RNA transfection. Malone RW, Felgner PL, Verma IM. Proc Natl Acad Sci (PNAS) U S A. 1989;86(16):6077-81. Cited in 749 articles.

• Direct gene transfer into mouse muscle in vivo. Wolff JA, Malone RW, et al. Science. 1990;247(4949 Pt 1):1465-8. Cited in 4,750 articles. Note that Robert was a student at Northwestern, and was never affiliated with University of Wisc.

• High levels of messenger RNA expression following cationic liposome mediated transfection tissue cultured cells. Malone R, Kumar R, Felgner P. NIH Conference: “Self-Cleaving RNA as an Anti-HIV Agent (abstract). Washington, DC June 1989.

• Cationic liposome-mediated RNA transfection. Dwarki VJ, Malone RW, Verma IM. Methods Enzymol. 1993;217:644-54. Cited in: 102 articles.

• Delivery of exogenous DNA (includes mRNA) sequences in a mammal P Felgner, JA Wolff, GH Rhodes, R Malone, D Carson. Biotechnology Advances 1993: 15 (3-4), 763-763

For a deeper dive into the actual data, patent disclosures, meeting notes, lab books, etc, go to this webpage.

Patents and papers - from the 1990s

• DNA vaccines for eliciting a mucosal immune response (includes mRNA). US Pat. Ser. No. 6,110,898. Inventors: RW Malone and Jill Glasspool Malone. Date of issue: 8/29/00. Cited in 40 articles. Priority Date: 1996.

• Formulations and methods for generating active cytofectin: polynucleotide transfection complexes. Robert W Malone, et al. US Pat. Ser. No. 5,925,623 7/20/99.

• Cationic Transport Reagents. US Pat. Ser. No. 5,892,071 Robert W Malone, et. al. issued 4/06/99.

• Polyfunctional cationic cytofectins, formulations and methods for generating active cytofectin: polynucleotide transfection complexes. Robert W Malone, et. al. US Pat. Ser. No. 5,824,812 issued 10/20/98.

• Cationic Transport Reagents. Robert W Malone, et. al. US Pat. Ser. No. 5,744,625 issued 4/28/98.

• Cationic Transport Reagents. Robert W Malone, et. al. US Pat. Ser. No. 5,527,928, date of issue: 6/18/96.

• Marked enhancement of macaque respiratory tissue transfection by aurintricarboxylic acid. Glasspool-Malone J, …, Malone RW. Gene Med. 2002;4(3):323-2.

• Enhancing direct in vivo transfection with nuclease inhibitors and pulsed electrical fields. Glasspool-Malone J, Malone RW. In Gene Therapy Methods: Methods Enzymol. 2002;346:72-91

• Cutaneous transfection and immune responses to intradermal nucleic acid vaccination are significantly enhanced by in vivo electropermeabilization. Drabick JJ, Glasspool-Malone J, …, Malone RW. Mol Ther. 2001;3(2):249-55. Cited in 192 articles.

• Theory and in vivo application of electroporative gene delivery. Somiari S, Glasspool-Malone J, … Malone RW. Mol Ther. 2000;2(3):178-87. Cited in 345 articles.

• Efficient nonviral cutaneous transfection. Glasspool-Malone J, …, Malone RW. Mol Ther. 2000;2(2):140-6. Cited in 138 articles.

• Developing dendritic cell polynucleotide vaccination for prostate cancer immunotherapy. Berlyn KA, …, Malone RW J Biotechnol. 1999;73(2-3):155-79

• Models of Cationic Liposome Mediated Transfection. Gene Therapy and Molecular Biology. Ahearn A, Malone RW. Vol 4. Gene Therapy and Molecular Biology 1999;4

• Cationic lipid-mediated gene delivery to murine lung: correlation of lipid hydration with in vivo transfection activity. Bennett MJ, …, Malone RW, Nantz MH. J Med Chem. 1997;40(25):4069-78

• Considerations for the design of improved cationic amphiphile-based transfection reagents. Bennett MJ, …, Malone RW. Journal of Liposome Research 1996;6(3):545-65

• Structural and functional analysis of cationic transfection lipids: the hydrophobic domain. Balasubramaniam RP, …, Malone RW. Gene Ther. 1996;3(2):163-72. cited in 172 articles.

• A flexible approach to synthetic lipid ammonium salts for polynucleotide transfection. MJ Bennett, RW Malone, MH Nantz. Tetrahedron letters 36 (13), 2207-2210